Scleroderma Diffuse
Mostrando 1-12 de 19 artigos, teses e dissertações.
-
1. Avaliação da vasculatura pulmonar na esclerose sistêmica / Evaluation of pulmonary vasculature in systemic sclerosis
A lesão pulmonar é a principal causa de morte da Esclerose Sistêmica (ES), e as alterações principais são: o acometimento intersticial e o vascular. No presente estudo analisamos através do microscópio confocal a laser 40 artérias pulmonares de pequeno e médio calibre de pacientes com ES e 16 controles. Medimos a área do lúmen, a área total do v
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 14/09/2011
-
2. Centrilobular fibrosis (CLF): a distinct histological pattern in systemic sclerosis with interstitial lung disease (ILD) / Fibrose centrilobular (FCL): um padrão histológico pulmonar distinto em pacientes com esclerose sistêmica e doença intersticial pulmonar
Objectives: CLF is a new histological pattern of idiopathic ILD associated to esophageal reflux. We have investigated its presence in SSc with lung involvement. Methods: 28 SSc patients were submitted to open lung biopsy. The specimens were classified according to the new consensus classification of idiopathic interstitial pneumonia and to the diagnostic cri
Publicado em: 2007
-
3. Humoral immune response characterization of the type V collagen induced scleroderma experimental model / Caracterização da resposta imune em modelo experimental de esclerodermia induzida por colágeno tipo V
Experimental models for human diseases are of utmost importance, since they allow the study of their pathogenesis and therapeutic approach. In this group we can include the experimental model of collagen V-induced scleroderma, in rabbits, with histological alterations (skin, lung and kidney) similar to those observed in humans. Auto-immune diseases have an u
Publicado em: 2005
-
4. Scl-86, a marker antigen for diffuse scleroderma.
More than 300 sera from patients with a connective tissue disease were analyzed with the immunoblotting technique. The presence of autoantibodies against an 86,000-mol wt marker antigen for diffuse scleroderma (Scl-86) was found in 14 out of 33 patients with scleroderma. The presence of anti-Scl-86 antibodies seemed to correlate with the diagnosis of diffuse
-
5. Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma).
Cell-mediated immunity to skin extracts was studied by the macrophage migration inhibition test, lymphocyte transformation, and direct cytotoxicity to skin fibroblasts, in normal individuals and patients with progressive systemic sclerosis. The latter included 18 individuals with diffuse scleroderma and 12 with the CREST syndrome, a variant form of systemic
-
6. Treatment of scleroderma heart by D-penicillamine.
A case of severe diffuse systemic sclerosis with cardiomegaly and cardiac failure is described. Treatment with D-penicillamine caused a pronounced decrease in heart size, together with clinical improvement. The use of penicillamine in scleroderma heart has not previously been reported.
-
7. Autoantibodies in childhood scleroderma.
The clinical presentation of scleroderma in childhood is even more varied than in adult life. This study of 19 children shows that antinuclear antibodies (ANA) detected on the HEp2 cell substrate are just as common as in the adult disorders. All seven children with diffuse scleroderma or acrosclerosis were ANA positive, as were eight of the 12 with more loca
-
8. Treatment of systemic sclerosis.
Proper classification of patients into diffuse cutaneous and limited cutaneous subsets and the anticipation of complications are the keys to the management of subjects with systemic sclerosis (scleroderma). Patients with early diffuse disease and rapidly progressive skin thickening are at highest risk of developing serious disease of the internal organs (int
-
9. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
BMJ Group.
-
10. Systemic and cell type-specific gene expression patterns in scleroderma skin
We used DNA microarrays representing >12,000 human genes to characterize gene expression patterns in skin biopsies from individuals with a diagnosis of systemic sclerosis with diffuse scleroderma. We found consistent differences in the patterns of gene expression between skin biopsies from individuals with scleroderma and those from normal, unaffected indivi
National Academy of Sciences.
-
11. Scleroderma in childhood.
Scleroderma in childhood is a rare but confusing disorder. Systemic and diffuse disease do occur but are uncommon. Much more common are local lesions of different types which can be multiple; these are often associated with joint symptoms and the development of joint contractures and tendon contractures due to nodule formation. In such circumstances the cond
-
12. The clinical relevance of autoantibodies in scleroderma
Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other conne
BioMed Central.